Neurolipocytoma

Dr. Samantha A. Vergano, MD - Clinical Genetics, Genomics, Cytogenetics, Biochemical Genetics Specialist. Dr. Samantha A. Vergano, MD - Clinical Genetics, Genomics, Cytogenetics, Biochemical Genetics Specialist.
December 18, 2025
11 Views
Rx Cancer (A - Z)

Neurolipocytoma is a very rare, usually slow-growing brain tumor that most often starts in the cerebellum (the back part of the brain that helps balance and coordination). The tumor cells look mainly like neuronal (nerve) cells, and many of the cells also contain fat (lipid) inside them, which is why the name includes “lipo.” [Source] Radiopaedia+2PMC+2

Neurolipocytoma is a very rare brain tumor name that is often used to mean cerebellar liponeurocytoma. It usually grows in the cerebellum (the back-lower part of the brain that helps balance and coordination). The tumor cells look partly like nerve-type cells and partly like fat-like (lipid) cells under a microscope. It is usually slow-growing, but it can come back (recur) even years later, so long follow-up is important. [Source: rare tumor reviews + WHO-grade discussion in published case literature]. PMC

Doctors now usually call it cerebellar liponeurocytoma, and many medical references list neurolipocytoma as an older or alternative name. In modern classifications it is generally treated as a WHO grade 2 tumor, which means it is often not aggressive like high-grade cancers, but it can come back (recur) and needs long follow-up. [Source] PMC+3Radiopaedia+3PubMed+3

This tumor causes problems mainly because it takes up space in the tight area of the posterior fossa (near the brainstem and the fluid spaces). When it grows, it can press on nearby brain tissue or block normal flow of brain fluid, which can lead to pressure symptoms like headache, vomiting, or balance trouble. [Source] The Journal of Neurosurgery+2PMC+2

Other names

These are names you may see in books, reports, or old papers for the same tumor (or very close variants). [Source] PMC+1

  • Cerebellar liponeurocytoma (most common modern name). [Source] PubMed+1

  • Liponeurocytoma (short form). [Source] PubMed+1

  • Neurolipocytoma (older/alternative name). [Source] Radiopaedia+1

  • Lipomatous glioneurocytoma / lipomatous variants (used by some authors because the tumor may show mixed neuronal and glial features plus fat). [Source] J Pathol Transl Med+1

  • Lipidized medulloblastoma / lipomatous medulloblastoma (older confusing names; now considered misleading in many cases). [Source] PMC+1

Types

Because the tumor is rare, “types” are usually described by location and clinical behavior, not by many official subtypes. [Source] PubMed+1

  • Typical cerebellar (posterior fossa) neurolipocytoma: The classic form in the cerebellum. Symptoms usually come from balance area pressure or fluid blockage. [Source] Radiopaedia+2PubMed+2

  • Extra-cerebellar / supratentorial variant: Rare cases have been reported outside the cerebellum (higher parts of the brain). Doctors still diagnose it by the same cell features. [Source] J Pathol Transl Med+1

  • Recurrent neurolipocytoma: A tumor that comes back months or years after surgery. Recurrence is one reason it is treated as WHO grade 2 and followed for a long time. [Source] PMC+2PMC+2

  • Rare “spread” cases (CSF seeding/spinal deposits): Very uncommon, but a few reports describe spread through brain fluid pathways. This is exceptional, not the usual pattern. [Source] Surgical Neurology International+1

Causes

Important truth: The exact cause is unknown, and confirmed “causes” have not been established for this rare tumor. So the list below is written as possible causes or risk factors scientists consider, mixing (1) what is known about many brain tumors in general and (2) what is reported about this tumor’s biology. [Source] J Pathol Transl Med+3The Journal of Neurosurgery+3American Cancer Society+3

  1. Random DNA changes (somatic mutations): Many tumors start when one cell gets DNA changes that make it grow too much. These changes are often not inherited and happen during life. [Source] Cancer.gov+2Cancer.gov+2

  2. Normal aging of cells: Somatic mutations can slowly build up as people get older. This may partly explain why many brain tumors are more common in adults. [Source] NCBI+2PMC+2

  3. Errors during cell division: When cells copy DNA, small errors can happen. Most are repaired, but some remain and may help a tumor start. [Source] Canadian Cancer Society+1

  4. Problems in DNA repair systems: If the cell’s repair tools do not work well, mutations can pile up more easily. This idea is part of modern cancer biology. [Source] NCBI+1

  5. TP53 mutation in some cases (tumor biology clue): Studies report TP53 mutations in a portion of cerebellar liponeurocytomas. This does not prove a cause, but it suggests a growth-control pathway may be involved. [Source] J Pathol Transl Med+2PubMed+2

  6. Other chromosome/gene changes (still being studied): Research describes cytogenetic findings in some cases, but there is no single “one mutation” that explains all tumors yet. [Source] PMC+2SpringerLink+2

  7. Cell-of-origin problem in the cerebellum (hypothesis): Many authors think it may start from a cell that can develop into neuronal/glial-type cells in the cerebellum, but this is still not certain. [Source] The Journal of Neurosurgery+1

  8. Abnormal “maturation” toward fat (lipidization): A key feature is fat inside tumor cells. This is more a feature than a cause, but it suggests unusual metabolism or differentiation inside the tumor. [Source] Radiopaedia+2J Pathol Transl Med+2

  9. Ionizing radiation exposure (general brain-tumor risk): Radiation exposure to the head is one of the best-validated environmental risk factors for brain tumors overall. It is not proven for neurolipocytoma specifically. [Source] American Cancer Society+2PMC+2

  10. Past radiation therapy (general mechanism): Radiation can damage DNA in normal cells and rarely lead to new tumors years later. This is a general concept, not specific proof for this tumor. [Source] American Cancer Society+1

  11. Rare inherited cancer-predisposition syndromes (general CNS tumor risk): Some inherited conditions can raise CNS tumor risk. For neurolipocytoma, hereditary forms are reported as not clearly established/very uncommon. [Source] NINDS+1

  12. Family history as a general risk sign: In some brain tumors, family history can matter, but for this tumor specifically, strong family patterns are not well shown. [Source] NINDS+1

  13. Immune system suppression (for some CNS tumors): Immune suppression raises risk for some CNS tumors (for example primary CNS lymphoma). This is not known as a cause of neurolipocytoma, but it is part of CNS tumor risk science. [Source] Cancer.gov

  14. Certain chemical exposures (limited to specific tumor types): Some exposures are discussed as possible risks for certain brain tumors (example: vinyl chloride for glioma). This is not proven for neurolipocytoma. [Source] Cancer.gov

  15. Epigenetic changes (gene “switch” changes): Some tumors involve changes in how genes are turned on/off, not only DNA sequence changes. This area is still developing for many CNS tumors. [Source] PMC+1

  16. Chance “one-cell” start (sporadic origin): Many cancers are sporadic, meaning they begin by chance in one cell rather than being inherited. This is the most likely pattern for many rare tumors too. [Source] Canadian Cancer Society+1

  17. Adult-age predominance (an association, not a cause): Liponeurocytoma mainly appears in adults, which hints that time-related changes may matter, but age itself is not a direct cause. [Source] PubMed+1

  18. Posterior fossa biology (an association): The tumor’s strong preference for the posterior fossa suggests local cell types there may be involved, but the “why” is still unknown. [Source] PubMed+1

  19. Higher growth index in some tumors (recurrence biology): A higher Ki-67/MIB-1 index is linked with stronger growth and recurrence risk in reports. This explains behavior more than the first cause. [Source] PMC+2Rural Neuro Practice+2

  20. Unknown (honest “cause” entry): For this tumor, doctors often must say “cause unknown,” because good studies are hard when only a small number of cases exist. [Source] The Journal of Neurosurgery+2PubMed+2

Symptoms

Symptoms depend on the tumor size, exact place in the cerebellum, and whether brain fluid flow is blocked. [Source] The Journal of Neurosurgery+2PMC+2

  1. Headache: A growing mass can raise pressure inside the skull or stretch pain-sensitive structures, causing headaches that may get worse over time. [Source] The Journal of Neurosurgery+2PMC+2

  2. Nausea: Increased brain pressure can irritate brain centers that control nausea. This often comes with headache. [Source] The Journal of Neurosurgery+2The Journal of Neurosurgery+2

  3. Vomiting: Vomiting can happen when pressure rises or when the posterior fossa area is affected. It can be worse in the morning for some people. [Source] The Journal of Neurosurgery+2PMC+2

  4. Dizziness: The cerebellum helps with balance, so pressure or irritation there can feel like spinning or unsteadiness. [Source] The Journal of Neurosurgery+2The Journal of Neurosurgery+2

  5. Gait unsteadiness (ataxia): People may walk with a wide base, stagger, or feel they cannot control steps well because cerebellar circuits are disturbed. [Source] The Journal of Neurosurgery+2The Journal of Neurosurgery+2

  6. Poor coordination of hands: You may drop things, miss targets, or feel clumsy, because the cerebellum helps fine movement timing. [Source] NCBI+1

  7. Slurred speech (dysarthria): The cerebellum helps coordinate speech muscles. Pressure can make speech sound slow or “scanning.” [Source] The Journal of Neurosurgery+1

  8. Nystagmus (jerky eye movements): Cerebellar and brainstem pathways help steady the eyes. Disturbance can cause jumping eye movements. [Source] The Journal of Neurosurgery+1

  9. Blurred vision: This can occur due to pressure effects, hydrocephalus, or eye movement problems linked to posterior fossa involvement. [Source] The Journal of Neurosurgery+2SpringerLink+2

  10. Double vision (diplopia): If pathways for eye alignment are affected, eyes may not move together, causing double vision. [Source] The Journal of Neurosurgery+1

  11. Tinnitus (ringing in the ear): Some reported cases include ear ringing, possibly from nearby brainstem/cerebellopontine region effects. [Source] The Journal of Neurosurgery+1

  12. Hiccups: Hiccups can happen when brainstem-related reflex pathways are irritated; this has been described in case reports of posterior fossa tumors. [Source] The Journal of Neurosurgery+1

  13. Weakness or fatigue: These can happen indirectly from poor balance, poor eating due to nausea, sleep disruption, or general illness stress. [Source] PMC+1

  14. Confusion or sleepiness (from hydrocephalus/pressure): If fluid flow is blocked, pressure can rise and affect thinking and alertness. [Source] SpringerLink+1

  15. Seizures (uncommon for pure cerebellar tumors, but possible): Seizures are more typical with tumors in the brain’s upper parts, but any brain irritation can sometimes be linked with seizure-like events and needs medical checking. [Source] Mayo Clinic+1

Diagnostic tests

Diagnosis usually uses a mix of clinical exam + brain imaging, and final confirmation is by pathology (looking at tumor tissue). [Source] PubMed+2PMC+2

Physical exam tests

  1. Full neurological exam: A clinician checks strength, reflexes, sensation, coordination, and thinking. Cerebellar tumors often show coordination and balance signs. [Source] NCBI+1

  2. Cranial nerve exam: This checks eye movement, facial movement, hearing, swallowing, and other brainstem-linked functions that can be affected by posterior fossa pressure. [Source] The Journal of Neurosurgery+1

  3. Eye exam for papilledema (fundoscopy): Papilledema means optic disc swelling from high intracranial pressure. It is an important warning sign and must be taken seriously. [Source] NCBI+2EyeWiki+2

  4. Gait observation: Simply watching how a person stands, turns, and walks can show ataxia or imbalance linked to cerebellar dysfunction. [Source] NCBI+1

Manual tests (bedside coordination/balance tests)

  1. Finger-to-nose test: The person touches their nose and the examiner’s finger. Missing the target or shaking near the target can suggest cerebellar trouble. [Source] NCBI+1

  2. Heel-to-shin test: The person slides the heel down the opposite shin. A side-to-side “wobble” can suggest cerebellar problems. [Source] NCBI+1

  3. Rapid alternating movements (dysdiadochokinesia check): The person flips hands quickly (like turning pages). Slow, irregular, or clumsy movement can be a cerebellar sign. [Source] NCBI+1

  4. Romberg test: This checks balance when standing with feet together, eyes open then closed. It helps separate balance pathway problems (it is not only for cerebellum, but still useful in the balance workup). [Source] NCBI

  5. Tandem gait (heel-to-toe walking): Walking in a straight line heel-to-toe can uncover mild balance and coordination problems. [Source] NCBI+1

Lab and pathological tests

  1. Complete blood count (CBC): This is not specific for the tumor, but it helps evaluate anemia, infection, and fitness for surgery or procedures. [Source] PubMed+1

  2. Metabolic panel (kidney/liver salts): Also not tumor-specific, but important before imaging contrast, anesthesia, or surgery planning. [Source] PMC+1

  3. Coagulation tests (PT/INR, aPTT): These check blood-clotting safety before biopsy or surgery, because brain procedures need careful bleeding control. [Source] PMC+1

  4. Histopathology (microscope exam of tumor tissue): This is the main confirmation test. Pathologists look for neurocytic-type cells and areas showing fat (lipidization). [Source] J Pathol Transl Med+2PubMed+2

  5. Immunohistochemistry (IHC) markers: Tests like synaptophysin and other neuronal markers help confirm neuronal differentiation, and GFAP may show some glial features in some cases. [Source] J Pathol Transl Med+1

  6. Ki-67 / MIB-1 proliferation index: This measures how many cells are actively dividing. A higher index can suggest higher recurrence risk and helps guide follow-up planning. [Source] PMC+2Rural Neuro Practice+2

Electrodiagnostic tests

  1. EEG (electroencephalogram): EEG records brain electrical activity. It is mainly used when seizures or seizure-like events are suspected, or to support seizure diagnosis. [Source] Mayo Clinic+1

  2. Evoked potentials (VEP/BAEP/SSEP) or intra-operative monitoring: These tests measure pathway signals (vision, hearing/brainstem, sensation). They may be used in some cases to support assessment or during surgery near critical pathways. [Source] The Journal of Neurosurgery+1

Imaging tests

  1. CT scan of the brain: CT can quickly show a mass, hydrocephalus, calcification, and fat-density parts, which is helpful because this tumor may contain fatty components. [Source] PMC+1

  2. MRI brain with and without contrast (including fat-suppressed sequences): MRI is the key imaging test for detail. Fat-related signals and tumor boundaries can help suggest liponeurocytoma before surgery. [Source] PMC+2Rural Neuro Practice+2

  3. MRI of the spine (when needed): This is not routine for every patient, but it can be considered if symptoms suggest spinal involvement or if doctors are checking for rare CSF spread in special cases. [Source] Surgical Neurology International+1

Non-pharmacological treatments (therapies and other care)

  1. Active surveillance (watchful waiting): If the tumor is small, slow, and not causing dangerous pressure, doctors may watch with regular MRI scans. Purpose: avoid risks of treatment when not needed. Mechanism: early detection of growth so treatment can start at the right time. [Source: rare tumor follow-up recommendations]. FDA Access Data+1

  2. Regular MRI follow-up schedule: MRI is used repeatedly after treatment to check for recurrence. Purpose: find regrowth early. Mechanism: MRI shows changes in tumor size and brain swelling before symptoms become severe. [Source: recurrence and long-term follow-up discussions]. FDA Access Data+1

  3. Neuro-rehabilitation program: A rehab plan helps with balance, walking, hand skills, and daily tasks after surgery or radiation. Purpose: restore independence. Mechanism: repeated practice trains the brain to re-learn movements and improve coordination. [Source: brain tumor supportive care/rehab guidance]. NCCN+1

  4. Physical therapy (PT): PT focuses on strength, balance, posture, and safe walking. Purpose: reduce falls and dizziness. Mechanism: balance exercises retrain cerebellar pathways and improve muscle control. [Source: rehabilitation in brain tumor care]. NCCN+1

  5. Occupational therapy (OT): OT helps with writing, dressing, eating, and school/work skills. Purpose: improve daily function. Mechanism: task-based training builds new routines and compensations when coordination is reduced. [Source: brain tumor rehab/supportive care]. NCCN+1

  6. Speech and swallowing therapy: Some people have slurred speech or swallowing trouble if brain pathways are affected. Purpose: safer eating and clearer speech. Mechanism: targeted muscle and coordination exercises improve timing and strength. [Source: supportive care in CNS tumors]. Cancer.gov+1

  7. Vestibular rehabilitation: Special exercises can reduce vertigo and improve gaze stability. Purpose: less dizziness and nausea. Mechanism: repeated head-eye training helps the brain adapt to balance signals. [Source: neuro-rehab principles in CNS care]. NCCN+1

  8. Cognitive rehabilitation: If attention, memory, or processing speed is affected, cognitive rehab helps. Purpose: better learning and daily planning. Mechanism: practice + strategies (notes, schedules) reduce “brain fog” and improve function. [Source: CNS tumor supportive care]. Cancer.gov+1

  9. Psychological counseling: Anxiety and fear of recurrence are common. Purpose: coping and emotional stability. Mechanism: therapy methods (like CBT skills) reduce stress responses and improve sleep and motivation. [Source: supportive/palliative care guidance]. Cancer.gov+1

  10. Family education and safety planning: Families learn warning signs (pressure symptoms, seizures) and how to respond. Purpose: faster help in emergencies. Mechanism: clear plans reduce delay and reduce complications. [Source: CNS tumor supportive care]. Cancer.gov+1

  11. School/work accommodations: Extra time, rest breaks, reduced load, or screen adjustments can help. Purpose: protect learning while recovering. Mechanism: lowering overload reduces headache and fatigue and supports brain healing. [Source: neuro-rehab/supportive care concepts]. NCCN+1

  12. Nutrition counseling (non-drug): A dietitian can plan easy-to-eat, high-protein meals during recovery. Purpose: prevent weight loss and weakness. Mechanism: adequate calories and protein support wound healing and muscle repair. [Source: cancer supportive care nutrition principles]. Cancer.gov+1

  13. Hydration plan: Dehydration worsens dizziness, constipation, and fatigue. Purpose: stable energy and safer recovery. Mechanism: fluids support blood pressure, kidney function, and medication tolerance. [Source: supportive care principles]. Cancer.gov+1

  14. Sleep optimization: Regular sleep schedule and dark, quiet room can reduce headache and fatigue. Purpose: better brain recovery. Mechanism: sleep supports brain repair, memory, and mood regulation. [Source: supportive care principles]. Cancer.gov+1

  15. Stress-reduction practices: Breathing exercises, mindfulness, gentle yoga (if safe) can help. Purpose: calmer nervous system. Mechanism: lowers stress hormones that can worsen sleep, pain sensitivity, and nausea. [Source: supportive care guidance]. Cancer.gov+1

  16. Pain self-management skills (non-drug): Ice/heat (if approved), pacing, posture training, relaxation. Purpose: less headache/neck pain. Mechanism: reduces muscle tension and pain amplification. [Source: supportive care guidance]. Cancer.gov+1

  17. Nausea control without medicines: Small meals, ginger-like foods (if tolerated), avoiding strong smells, slow position changes. Purpose: fewer vomiting episodes. Mechanism: reduces stomach trigger and vestibular trigger load. [Source: cancer supportive care concepts]. Cancer.gov+1

  18. Radiation therapy (when needed): Sometimes used after incomplete removal or recurrence (doctor-decided). Purpose: control remaining tumor cells. Mechanism: radiation damages tumor DNA so cells cannot keep dividing. [Source: CNS tumor treatment principles + recurrence discussions]. Cancer.gov+1

  19. Stereotactic radiosurgery (selected cases): Very focused radiation for small targets. Purpose: treat small residual/recurrent areas with less exposure to normal brain. Mechanism: high-precision beams concentrate dose in the tumor area. [Source: CNS tumor radiation approaches]. Cancer.gov+1

  20. Palliative/supportive care team involvement: This is not “end-of-life only.” It helps symptoms, sleep, mood, and family support. Purpose: better quality of life during any stage. Mechanism: coordinated symptom control and counseling reduces suffering and improves function. [Source: supportive/palliative care guidance]. Cancer.gov+1

Drug treatments

These medicines are prescription-only and must be chosen by a specialist. Also, there are no FDA-approved drugs specifically for “neurolipocytoma / cerebellar liponeurocytoma”, so medicines are usually for (a) other brain tumor conditions, (b) recurrence situations, or (c) symptom control like swelling, seizures, nausea, or pressure. [Source: rarity of tumor + standard CNS care approach]. FDA Access Data+1

  1. Temozolomide (TEMODAR) — alkylating chemotherapy. Example label dose/time: 75 mg/m² daily during radiotherapy (42 days), then 150 mg/m² daily on Days 1–5 of each 28-day cycle (may increase to 200 mg/m² in later cycles). Purpose: kill dividing tumor cells in certain brain cancers. Mechanism: damages tumor DNA. Side effects: low blood counts, nausea, fatigue, infection risk. [FDA label]. FDA Access Data

  2. Bevacizumab (AVASTIN) — anti-VEGF antibody (anti-angiogenesis). Example label dose/time (glioblastoma): 10 mg/kg every 2 weeks. Purpose: reduce tumor blood-vessel growth and swelling in specific cancers. Mechanism: blocks VEGF signaling, lowering abnormal vessel leak. Side effects: high blood pressure, bleeding, clot risk, wound-healing problems. [FDA label]. FDA Access Data

  3. Lomustine (GLEOSTINE) — nitrosourea chemotherapy. Example label dose/time: 130 mg/m² as a single oral dose (courses are spaced because blood counts can drop later). Purpose: used in some brain tumor regimens. Mechanism: DNA alkylation/cross-linking. Side effects: delayed low platelets/white cells, nausea, liver effects. [FDA label]. FDA Access Data

  4. Carmustine (BiCNU) IV — nitrosourea chemotherapy. Example label dose/time: 150–200 mg/m² IV every 6 weeks (or divided 75–100 mg/m² on 2 days). Purpose: used for certain cancers including some CNS tumor regimens. Mechanism: DNA/RNA alkylation. Side effects: delayed low blood counts, lung toxicity risk, nausea/vomiting. [FDA label]. FDA Access Data

  5. Carmustine implant (local wafer, when used in brain surgery settings) — local chemotherapy at the tumor bed. Purpose: place medicine where tumor was removed to expose remaining cells. Mechanism: slow local release of carmustine. Side effects: wound infection, swelling, seizures, healing issues. [FDA accessdata labeling exists for implant products]. FDA Access Data

  6. Vincristine (vincristine sulfate injection) — vinca alkaloid chemotherapy. Example label dose/time: adults 1.4 mg/m² IV weekly (pediatric dosing differs). Purpose: part of combination chemo in several cancers. Mechanism: blocks microtubules → stops cell division. Side effects: nerve damage (tingling/weakness), constipation/ileus, hair loss. [FDA label]. FDA Access Data

  7. Cisplatin (cisplatin injection) — platinum chemotherapy. Dose/time: dosing varies by regimen and cancer type and must be individualized. Purpose: sometimes used in CNS tumor protocols and other cancers. Mechanism: DNA cross-linking → tumor cell death. Side effects: kidney toxicity, hearing changes, nausea/vomiting, neuropathy. [FDA label source]. FDA Access Data

  8. Carboplatin (carboplatin injection) — platinum chemotherapy. Dose/time: dosing is often calculated (e.g., by kidney function formulas) and regimen-dependent. Purpose: alternative platinum agent in some protocols. Mechanism: DNA cross-linking. Side effects: low platelets, nausea, kidney effects (usually less than cisplatin), allergy reactions. [FDA label source]. FDA Access Data

  9. Irinotecan (irinotecan injection) — topoisomerase-I inhibitor. Dose/time: regimen-dependent. Purpose: used in some recurrent brain tumor regimens (doctor-selected). Mechanism: blocks DNA unwinding/repair in dividing cells. Side effects: diarrhea (can be severe), low blood counts, fatigue. [FDA label source]. FDA Access Data

  10. Methotrexate (injection) — antimetabolite chemotherapy. Dose/time: varies widely; high-dose regimens are specialist-only. Purpose: key medicine in CNS lymphoma protocols (not specific to neurolipocytoma). Mechanism: blocks folate pathways needed for DNA building. Side effects: mouth sores, liver effects, low blood counts; requires careful monitoring. [FDA label source]. FDA Access Data

  11. Cytarabine (injection) — antimetabolite chemotherapy. Dose/time: regimen-dependent. Purpose: used in leukemia/lymphoma regimens, sometimes involving CNS-directed therapy. Mechanism: faulty DNA building block → stops DNA replication. Side effects: low blood counts, infection risk, nausea, liver effects. [FDA label source]. PMC

  12. Rituximab (RITUXAN) — anti-CD20 antibody. Dose/time: regimen-dependent. Purpose: used for B-cell lymphomas (including CNS lymphoma protocols in some settings). Mechanism: targets CD20 on B cells → immune-mediated cell killing. Side effects: infusion reactions, infection risk, rare severe skin reactions. [FDA label source]. PMC

  13. Pembrolizumab (KEYTRUDA) — PD-1 immune checkpoint inhibitor. Dose/time: label dosing depends on indication (commonly given every 3 or 6 weeks in adult oncology settings). Purpose: helps the immune system attack certain cancers. Mechanism: blocks PD-1 “brake” on immune cells. Side effects: immune-related inflammation (skin, gut, lungs, thyroid). [FDA label source]. Rural Neuro Practice

  14. Nivolumab (OPDIVO) — PD-1 immune checkpoint inhibitor. Dose/time: regimen-dependent. Purpose: used in several cancers; sometimes considered in selected CNS tumor situations by specialists. Mechanism: PD-1 blockade boosts anti-tumor immune response. Side effects: immune-related colitis, hepatitis, pneumonitis, endocrine issues. [FDA label source]. Office of Dietary Supplements

  15. Dexamethasone (DECADRON and generics) — corticosteroid. Dose/time: individualized; used short-term for brain swelling/pressure symptoms. Purpose: reduce edema around tumors. Mechanism: lowers inflammatory leakage and swelling. Side effects: high blood sugar, mood changes, insomnia, infection risk, stomach irritation. [FDA label source]. FDA Access Data

  16. Levetiracetam (KEPPRA) — anti-seizure medicine. Dose/time: individualized; label includes adult dosing tables and kidney-based adjustments. Purpose: prevent or control seizures linked with brain lesions or surgery. Mechanism: stabilizes nerve signaling (SV2A binding). Side effects: sleepiness, dizziness, mood/irritability in some people. [FDA label]. FDA Access Data

  17. Ondansetron (ZOFRAN) — 5-HT3 anti-nausea medicine. Example label dose/time: adults may receive 24 mg once before highly emetogenic chemo; other schedules exist by situation. Purpose: reduce nausea/vomiting from chemo or radiation. Mechanism: blocks serotonin signals that trigger vomiting reflex. Side effects: constipation, headache, QT prolongation risk in some. [FDA label]. FDA Access Data

  18. Aprepitant (EMEND) — NK1 receptor antagonist anti-nausea medicine. Example label regimen: 125 mg Day 1 then 80 mg Days 2–3 (commonly used with other antiemetics). Purpose: prevent delayed chemo-related vomiting. Mechanism: blocks substance-P/NK1 signaling in the brain vomiting center. Side effects: fatigue, hiccups, drug interactions. [FDA label]. FDA Access Data

  19. Mannitol injection — osmotic diuretic. Purpose: reduce intracranial pressure and cerebral edema in urgent settings. Mechanism: pulls water out of brain tissue into blood so swelling drops. Side effects: dehydration, electrolyte imbalance, kidney stress (needs monitoring). [FDA label]. FDA Access Data

  20. Topotecan (topotecan injection) — topoisomerase-I inhibitor. Dose/time: regimen-dependent and specialist-only. Purpose: used in some cancers; sometimes explored in recurrent CNS tumors. Mechanism: blocks DNA repair during replication. Side effects: low white cells, infection risk, fatigue, nausea. [FDA label source]. FDA Access Dat

Dietary molecular supplements

Supplements do not treat the tumor, but they may help if you have a proven deficiency, poor appetite, or treatment side effects. Some supplements can also interact with chemotherapy or radiation, so a doctor/pharmacist should approve them first. [Source: cancer.gov supplement caution + NIH ODS guidance]. Cancer.gov+1

  1. Vitamin D: Helps bone strength and immune signaling. Dose: depends on blood level; many people aim for the recommended daily amount unless doctor prescribes more. Function: bone and muscle support. Mechanism: vitamin-D receptor changes gene activity for calcium absorption and immune balance. [NIH ODS]. Office of Dietary Supplements

  2. Omega-3 (EPA/DHA): May support heart health and help inflammation balance during recovery. Dose: varies by product; food sources (fish) are preferred. Function: nutrition support when appetite is low. Mechanism: changes membrane fats and inflammatory mediator production. [NIH ODS]. Office of Dietary Supplements

  3. Magnesium: Can help if low (cramps, poor intake). Dose: follow label/doctor; too much can cause diarrhea. Function: nerve and muscle function. Mechanism: supports enzyme reactions and nerve signaling stability. [NIH ODS]. Office of Dietary Supplements

  4. Vitamin B12: Helps nerve health and red blood cell formation. Dose: depends on diet and blood level. Function: supports energy and nerves during recovery. Mechanism: needed for myelin and DNA synthesis. [NIH ODS]. Office of Dietary Supplements

  5. Folate (folic acid/folate): Supports normal cell growth and blood cells. Dose: use recommended daily amount unless doctor advises. Function: helpful if dietary intake is low. Mechanism: needed for DNA building and methylation pathways. [NIH ODS]. Office of Dietary Supplements

  6. Zinc: Supports wound healing and immune defense. Dose: stay near recommended amount; excess can upset copper balance. Function: healing after surgery. Mechanism: enzyme cofactor for repair and immune cell function. [NIH ODS]. Office of Dietary Supplements

  7. Selenium: Supports thyroid function and antioxidant systems. Dose: teens 14–18: recommended 55 mcg/day. Function: nutrition support. Mechanism: part of selenoproteins that protect cells and help thyroid hormones. [NIH ODS]. Office of Dietary Supplements

  8. Calcium: Important for bones, especially if steroids reduce bone strength. Dose: teens 14–18: 1,300 mg/day from food + supplements if needed. Function: bone protection. Mechanism: mineral for bone structure and nerve conduction. [NIH ODS]. Office of Dietary Supplements

  9. Vitamin C: Helps collagen/wound healing and iron absorption. Dose: usually best from fruits/vegetables; supplements optional if diet is poor. Function: healing support. Mechanism: cofactor for collagen formation and antioxidant defense. [NIH ODS]. Office of Dietary Supplements

  10. Turmeric/curcumin (only with medical approval): Popular for inflammation claims, but evidence is mixed and it can interact with medicines. Dose: product-dependent; avoid high doses without supervision. Function: symptom support (some people). Mechanism: may affect inflammatory signaling pathways. [NCCIH safety guidance]. NCCIH

Immunity booster / regenerative / stem-cell support” medicines

These are used when blood counts drop from chemotherapy/radiation or in transplant settings. They are not tumor cures, but they can reduce infection/bleeding/anemia risks when a specialist decides they are needed. [Source: FDA labels]. FDA Access Data+1

  1. Filgrastim (NEUPOGEN): Dose: varies by situation; label describes weight-based dosing and clinical ANC response. Function: boosts neutrophils (infection-fighting white cells). Mechanism: G-CSF stimulates bone marrow to make neutrophils faster. [FDA label]. FDA Access Data

  2. Pegfilgrastim (NEULASTA): Dose/time: 6 mg once per chemotherapy cycle; not within 14 days before or 24 hours after cytotoxic chemo. Function: lowers infection risk from low neutrophils. Mechanism: long-acting G-CSF support of bone marrow recovery. [FDA label]. FDA Access Data

  3. Sargramostim (LEUKINE): Example label dose: 250 mcg/m²/day IV or SC in certain transplant-related settings (timing rules around chemo/radiation). Function: supports white blood cell recovery. Mechanism: GM-CSF stimulates marrow precursors to grow and mature. [FDA label]. FDA Access Data

  4. Epoetin alfa (EPOGEN/PROCRIT): Dose/time: varies by indication; used under strict rules for anemia in selected settings. Function: supports red blood cell production. Mechanism: acts like natural erythropoietin to stimulate RBC formation. Risks: clots, blood pressure rise (must be monitored). [FDA label]. FDA Access Data

  5. Romiplostim (NPLATE): Dose/time: weekly, individualized by platelet response (specialist-directed). Function: raises platelets in certain conditions. Mechanism: thrombopoietin receptor activation increases platelet production. Risks: clot risk, marrow changes (monitoring needed). [FDA label source]. Cancer.gov

  6. Plerixafor (MOZOBIL): Dose/time: used to mobilize stem cells for collection before transplant (specialist-only). Function: helps move stem cells into blood for collection. Mechanism: blocks CXCR4 so stem cells leave marrow temporarily. Side effects: diarrhea, injection reactions, dizziness. [FDA label source]. Cancer.gov

 Surgeries (procedures and why they are done)

  1. Posterior fossa craniotomy with gross total resection (GTR): The surgeon opens the skull in the back of the head to remove as much tumor as safely possible. Why: best chance of long-term control and symptom relief in many cases. [Source: liponeurocytoma case series/reviews]. FDA Access Data+1

  2. Subtotal resection (STR): Partial removal when the tumor is close to critical brain structures. Why: reduce pressure and symptoms while avoiding major neurologic injury. [Source: neurosurgical principles in posterior fossa tumors]. NCCN+1

  3. Repeat surgery for recurrence: If the tumor returns and is removable, surgeons may operate again. Why: recurrence can happen years later; removing regrowth can restore control. [Source: recurrence discussions]. FDA Access Data+1

  4. Stereotactic biopsy: A small sample is taken with image guidance when diagnosis is uncertain or removal is risky. Why: confirm the exact tumor type so the correct plan is chosen. [Source: CNS tumor diagnostic approach]. Cancer.gov+1

  5. CSF diversion surgery (EVD or VP shunt / ETV in selected cases): Used if the tumor blocks fluid flow and causes hydrocephalus. Why: lowers dangerous brain pressure and protects vision/brain function. [Source: CNS tumor supportive care]. Cancer.gov+1

Preventions

There is no proven way to prevent this rare tumor, but you can reduce general brain-health risks and catch problems early. [Source: rarity and limited known risk factors]. FDA Access Data+1

  1. Avoid unnecessary head radiation exposure (medical imaging only when needed). [General oncology safety]. Cancer.gov+1

  2. Protect your head from injury (helmet for bikes/motorbikes). [Brain health safety concepts]. Cancer.gov+1

  3. Do not smoke and avoid secondhand smoke (general cancer risk reduction). Cancer.gov+1

  4. Keep blood pressure controlled (helps brain vessel safety and surgery recovery). Cancer.gov+1

  5. Maintain healthy sleep and stress control (supports immune balance and recovery). Cancer.gov+1

  6. Seek early care for persistent neurologic symptoms (don’t ignore “new and worsening”). Cancer.gov+1

  7. Follow post-treatment MRI schedule strictly (best “prevention” of late complications is early detection). FDA Access Data+1

  8. Take seizure precautions if advised (sleep, hydration, avoid triggers). Cancer.gov+1

  9. Prevent infections during chemo/steroid use (hand hygiene, vaccines if doctor approves). Cancer.gov+1

  10. Use medicines only as prescribed (many brain-tumor drugs have serious risks). FDA Access Data+1

When to see doctors (urgent vs soon)

See a doctor urgently if you have: severe “worst” headache, repeated vomiting, fainting, new weakness, confusion, new seizure, trouble speaking, or vision changes—these can be signs of rising brain pressure or seizure activity. See a doctor soon if you have weeks of worsening imbalance, dizziness, morning headaches, or new coordination problems. [Source: CNS tumor symptom and supportive care guidance]. Cancer.gov+1

What to eat and what to avoid

  1. Eat: enough protein (eggs, fish, chicken, lentils) for healing. Avoid: skipping meals (worsens weakness). [Supportive nutrition principles]. Cancer.gov+1

  2. Eat: fruits/vegetables daily for vitamin C and fiber. Avoid: very low-fiber diet if constipation is present. [NIH ODS vitamin C + supportive care]. Office of Dietary Supplements+1

  3. Eat: calcium-rich foods (milk, yogurt) for bone health. Avoid: very salty foods if swelling or steroid side effects exist. [NIH ODS calcium + steroid supportive care]. Office of Dietary Supplements+1

  4. Eat: omega-3 foods (fish) if tolerated. Avoid: unknown “mega dose” fish oil without approval (bleeding risk in some). [NIH ODS omega-3]. Office of Dietary Supplements

  5. Eat: safe, well-cooked foods if immunity is low. Avoid: raw/unsafe street foods during neutropenia risk. [Supportive oncology safety]. FDA Access Data+1

  6. Eat: enough water and soups. Avoid: dehydration (worsens dizziness and constipation). [Supportive care]. Cancer.gov+1

  7. Eat: small frequent meals for nausea. Avoid: greasy/spicy heavy meals when vomiting risk is high. [Antiemetic supportive care concepts]. FDA Access Data+1

  8. Eat: foods with magnesium/zinc if intake is low (nuts, beans). Avoid: random high-dose mineral pills without guidance. [NIH ODS magnesium/zinc]. Office of Dietary Supplements+1

  9. Eat: iron-rich foods if anemia is present (meat, lentils) with medical advice. Avoid: iron pills unless a clinician confirms need. [NIH ODS iron]. Office of Dietary Supplements

  10. Eat: balanced “normal food” first. Avoid: “cancer cure diets” and extreme restrictions (they can cause malnutrition). [Cancer.gov supplement/diet caution]. Cancer.gov

FAQs

  1. Is neurolipocytoma cancer? It is usually a slow-growing rare tumor, but it can recur, so doctors treat it seriously. FDA Access Data+1

  2. Where does it happen? Most reports describe it in the cerebellum (back-lower brain). PMC

  3. What symptoms can it cause? Headache, vomiting, balance problems, dizziness, and sometimes seizures (from pressure or irritation). Cancer.gov+1

  4. What is the main treatment? Surgery to remove as much tumor as safely possible is often the key step. FDA Access Data+1

  5. Can it come back after surgery? Yes, recurrence has been reported even years later, so MRI follow-up matters. FDA Access Data+1

  6. Do I always need radiation? Not always. It depends on how much was removed and whether it recurs. FDA Access Data+1

  7. Are there specific FDA-approved drugs for this tumor? No specific FDA-approved drug exists for this exact rare tumor; medicines are usually for symptoms or other tumor settings. FDA Access Data+1

  8. Why do doctors use steroids like dexamethasone? To quickly reduce brain swelling and pressure symptoms. FDA Access Data

  9. Why might anti-seizure medicine be used? Brain irritation from a lesion or surgery can trigger seizures, so prevention/control may be needed. FDA Access Data+1

  10. What is the role of MRI? MRI tracks tumor size and swelling and helps detect recurrence early.

  11. Can diet cure it? No. Diet supports recovery and strength, but it does not remove a brain tumor.

  12. Are supplements always safe? No. Some interact with cancer treatments or affect bleeding; use only with medical approval.

  13. What complications should families watch for? Severe headache, repeated vomiting, new weakness, confusion, or seizure—these can be urgent.

  14. How long is recovery after surgery? It varies, but rehab (PT/OT/speech) can improve balance and daily skills over time.

  15. What specialists are usually involved? Neurosurgery, neurology, neuro-oncology, radiation oncology (if needed), and rehabilitation teams.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: December 17, 2025.

PDF Documents For This Disease Condition

  1. Rare Diseases and Medical Genetics.[rxharun.com]
  2. i2023_IFPMA_Rare_Diseases_Brochure_28Feb2017_FINAL.[rxharun.com]
  3. the-UK-rare-diseases-framework.[rxharun.com]
  4. National-Recommendations-for-Rare-Disease-Health-Care-Summary.[rxharun.com]
  5. History of rare diseases and their genetic.[rxharun.com]
  6. health-care-and-rare-disorders.[rxharun.com]
  7. Rare Disease Registries.[rxharun.com]
  8. autoimmune-Rare-Genetic-Diseases.[rxharun.com]
  9. Rare Genetic Diseases.[rxharun.com]
  10. rare-disease-day.[rxharun.com]
  11. Rare_Disease_Drugs_e.[rxharun.com]
  12. fda-CDER-Rare-Diseases-Public-Workshop-Master.[rxharun.com]
  13. rare-and-inherited-disease-eligibility-criteria.[rxharun.com]
  14. FDA-rare-disease-list.pdf-rxharun.com1 Human-Gene-Therapy-for-Rare Diseases_Jan_2020fda.[rxharun.com]
  15. FDA-rare-disease-lists.[rxharun.com]
  16. 30212783fnl_Rare Disease.[rxharun.com]
  17. FDA-rare-disease-list.[rxharun.com]
  18. List of rare disease.[rxharun.com]
  19. Genome Res.-2025-Steyaert-755-68.[rxharun.com]
  20. uk-practice-guidelines-for-variant-classification-v4-01-2020.[rxharun.com]
  21. PIIS2949774424010355.[rxharun.com]
  22. hidden-costs-2016.[rxharun.com]
  23. B156_CONF2-en.[rxharun.com]
  24. IRDiRC_State-of-Play-2018_Final.[rxharun.com]
  25. IRDR_2022Vol11No3_pp96_160.[rxharun.com]
  26. from-orphan-to-opportunity-mastering-rare-disease-launch-excellence.[rxharun.com]
  27. Rare disease fda.[rxharun.com]
  28. England-Rare-Diseases-Action-Plan-2022.[rxharun.com]
  29. SCRDAC 2024 Report.[rxharun.com]
  30. CORD-Rare-Disease-Survey_Full-Report_Feb-2870-2.[rxharun.com]
  31. Stats-behind-the-stories-Genetic-Alliance-UK-2024.[rxharun.com]
  32. rare-and-inherited-disease-eligibility-criteria-v2.[rxharun.com]
  33. ENG_White paper_A4_Digital_FINAL.[rxharun.com]
  34. UK_Strategy_for_Rare_Diseases.[rxharun.com]
  35. MalaysiaRareDiseaseList.[rxharun.com]
  36. EURORDISCARE_FULLBOOKr.[rxharun.com]
  37. EMHJ_1999_5_6_1104_1113.[rxharun.com]
  38. national-genomic-test-directory-rare-and-inherited-disease-eligibilitycriteria-.[rxharun.com]
  39. be-counted-052722-WEB.[rxharun.com]
  40. RDI-Resource-Map-AMR_MARCH-2024.[rxharun.com]
  41. genomic-analysis-of-rare-disease-brochure.[rxharun.com]
  42. List-of-rare-diseases.[rxharun.com]
  43. RDI-Resource-Map-AFROEMRO_APRIL[rxharun.com]
  44. rdnumbers.[rxharun.com] .
  45. Rare disease atoz .[rxharun.com]
  46. EmanPublisher_12_5830biosciences-.[rxharun.com]

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK208609/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC6279436/
  3. https://rarediseases.org/rare-diseases/
  4. https://rarediseases.info.nih.gov/diseases
  5. https://en.wikipedia.org/w/index.php?title=Category:Rare_diseases
  6. https://en.wikipedia.org/wiki/List_of_genetic_disorders
  7. https://en.wikipedia.org/wiki/Category:Genetic_diseases_and_disorders
  8. https://medlineplus.gov/genetics/condition/
  9. https://geneticalliance.org.uk/support-and-information/a-z-of-genetic-and-rare-conditions/
  10. https://www.fda.gov/patients/rare-diseases-fda
  11. https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/support-clinical-trials-advancing-rare-disease-therapeutics-start-pilot-program
  12. https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/jcph.2134
  13. https://www.mayoclinicproceedings.org/article/S0025-6196%2823%2900116-7/fulltext
  14. https://www.ncbi.nlm.nih.gov/mesh?
  15. https://www.rarediseasesinternational.org/working-with-the-who/
  16. https://ojrd.biomedcentral.com/articles/10.1186/s13023-024-03322-7
  17. https://www.rarediseasesnetwork.org/
  18. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/rare-disease
  19. https://www.raregenomics.org/rare-disease-list
  20. https://www.astrazeneca.com/our-therapy-areas/rare-disease.html
  21. https://bioresource.nihr.ac.uk/rare
  22. https://www.roche.com/solutions/focus-areas/neuroscience/rare-diseases
  23. https://geneticalliance.org.uk/support-and-information/a-z-of-genetic-and-rare-conditions/
  24. https://www.genomicsengland.co.uk/genomic-medicine/understanding-genomics/rare-disease-genomics
  25. https://www.oxfordhealth.nhs.uk/cit/resources/genetic-rare-disorders/
  26. https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-022-01026
  27. https://wikicure.fandom.com/wiki/Rare_Diseases
  28. https://www.wikidoc.org/index.php/List_of_genetic_disorders
  29. https://www.medschool.umaryland.edu/btbank/investigators/list-of-disorders/
  30. https://www.orpha.net/en/disease/list
  31. https://www.genetics.edu.au/SitePages/A-Z-genetic-conditions.aspx
  32. https://ojrd.biomedcentral.com/
  33. https://health.ec.europa.eu/rare-diseases-and-european-reference-networks/rare-diseases_en
  34. https://bioportal.bioontology.org/ontologies/ORDO
  35. https://www.orpha.net/en/disease/list
  36. https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions
  37. https://www.gao.gov/products/gao-25-106774
  38. https://www.gene.com/partners/what-we-are-looking-for/rare-diseases
  39. https://www.genome.gov/For-Patients-and-Families/Genetic-Disorders
  40. https://geneticalliance.org.uk/support-and-information/a-z-of-genetic-and-rare-conditions/
  41. https://my.clevelandclinic.org/health/diseases/21751-genetic-disorders
  42. https://globalgenes.org/rare-disease-facts/
  43. https://www.nidcd.nih.gov/directory/national-organization-rare-disorders-nord
  44. https://byjus.com/biology/genetic-disorders/
  45. https://www.cdc.gov/genomics-and-health/about/genetic-disorders.html
  46. https://www.genomicseducation.hee.nhs.uk/doc-type/genetic-conditions/
  47. https://www.thegenehome.com/basics-of-genetics/disease-examples
  48. https://www.oxfordhealth.nhs.uk/cit/resources/genetic-rare-disorders/
  49. https://www.pfizerclinicaltrials.com/our-research/rare-diseases
  50. https://clinicaltrials.gov/ct2/results?recrs
  51. https://apps.who.int/gb/ebwha/pdf_files/EB116/B116_3-en.pdf
  52. https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/sctm.21-0239
  53. https://www.nibib.nih.gov/
  54. https://www.nei.nih.gov/
  55. https://oxfordtreatment.com/
  56. https://www.nidcd.nih.gov/health/https://consumer.ftc.gov/articles/
  57. https://www.nccih.nih.gov/health
  58. https://catalog.ninds.nih.gov/
  59. https://www.aarda.org/diseaselist/
  60. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets
  61. https://www.nibib.nih.gov/
  62. https://www.nia.nih.gov/health/topics
  63. https://www.nichd.nih.gov/
  64. https://www.nimh.nih.gov/health/topics
  65. https://www.nichd.nih.gov/
  66. https://www.niehs.nih.gov/
  67. https://www.nimhd.nih.gov/
  68. https://www.nhlbi.nih.gov/health-topics
  69. https://obssr.od.nih.gov/.
  70. https://www.nichd.nih.gov/health/topics
  71. https://rarediseases.info.nih.gov/diseases
  72. https://beta.rarediseases.info.nih.gov/diseases
  73. https://orwh.od.nih.gov/

Related Articles

No widgets added. You can disable footer widget area in theme options - footer options

RxHarun
Logo